Is oxytocin an approved medicine?

Yes, and has been for decades — a widely used prescription medicine in obstetrics, acting on uterine smooth muscle. That use is well established and not in dispute.

Does oxytocin make people more trusting?

The early studies reported striking effects and the later, better-powered ones did not reproduce them at that size. Pooled analyses across clinical populations report limited and inconsistent effects, so the honest answer is that the literature does not support the claim as confidently as its popular reputation suggests.

Why is oxytocin research considered a replication problem?

Because effect sizes fell substantially as sample sizes grew and pre-registration became standard, and a methodological review identified design and analysis shortcomings in the existing studies. It is now a standard teaching example in the reproducibility literature.

Why does vasopressin matter when reading oxytocin studies?

The two hormones differ by only two amino acids and cross-react at each other's receptors. An effect attributed to oxytocin signalling may not be oxytocin-receptor-specific, and much of the behavioural work did not control for this.

What is oxytocin's place in chemistry history?

It was the first peptide hormone to be sequenced and totally synthesised, by du Vigneaud in 1953, work that won the 1955 Nobel Prize in Chemistry.

Research guides

Oxytocin: what the research says

A settled obstetric medicine with a behavioural literature that became one of psychology's clearest replication problems. Both halves belong together.

Available in the catalogue

Supplied as research material. Sizes and pricing are on the product page. Availability is not a statement about what a compound does.

OXYTOCIN
Hormonal & Reproductive

Oxytocin has two literatures that are almost never discussed together. One is an established clinical pharmacology going back seventy years. The other is a large body of behavioural work whose findings have shrunk considerably as the trials got better, and that shrinkage is itself the most useful thing published about the compound.

What the molecule is

A nine-amino-acid peptide with an internal disulfide bond closing six of its residues into a ring. It is made in the hypothalamus and released from the posterior pituitary. Its synthesis by du Vigneaud in 1953 was the first total synthesis of any peptide hormone and won the 1955 Nobel Prize in Chemistry — the compound is a landmark in peptide chemistry quite apart from its pharmacology.

Where the evidence is solid

It acts at the oxytocin receptor on uterine and mammary smooth muscle. That activity underpins its long and uncontroversial use as a prescription medicine in obstetrics, which is not what most people are reading about when they look this compound up.

Where it is not

A large behavioural literature investigated oxytocin in social cognition, trust and bonding, initially reporting striking effects. As sample sizes grew and pre-registration became standard, the pooled estimates fell. Meta-analyses across clinical populations have reported limited or inconsistent effects, an autism-specific meta-analysis reached a similarly cautious conclusion, and a methodological review of the field identified shortcomings in how the studies were designed and analysed.

There is also a specific pharmacological problem underneath the behavioural work: oxytocin differs from vasopressin by two amino acids, the two hormones cross-react at each other's receptors, and that cross-reactivity is a recurring confounder in interpreting behavioural results.

The interesting fact here is not that oxytocin does nothing. It is that a compound with genuinely settled pharmacology in one tissue accumulated a second literature that did not replicate at the effect sizes first reported — which is worth knowing before reading any confident claim about what it does to behaviour.

What studies reported

Each entry states what a study examined and the model it used. Nothing below describes an outcome for a person.

Everything below is drawn from published research, and each entry names the model the study used. Approval status varies by compound and by country, and nothing described here is supplied as a medicine or for use in a person.

Bonnieux et al. (2026)Neuroscience & Biobehavioral Reviews · 187:106749
Pooled clinical trials to assess whether intranasal oxytocin reduces symptoms across mental disorders, reporting on the size and consistency of the effects found.
human, meta-analysis of clinical trials Source
Kiani et al. (2023)CNS & Neurological Disorders - Drug Targets · 22(6):906–15
An updated pooled analysis of randomised controlled trials of oxytocin in adults with autism.
human, systematic review and meta-analysis of randomised trials Source

Adverse and null findings reported

Harms, tolerability observations, and trials that did not meet their endpoint. A negative result is a finding and is listed here rather than omitted.

Hasselbalch et al. (2020)Psychopharmacology · 237(10):2891–903
Examined methodological shortcomings in the existing studies of intranasal oxytocin in anorexia nervosa and healthy controls, reporting problems in design and analysis that limit what the literature can support.
human, systematic review and meta-analysis Source

What the research does not establish

An absence cannot be cited, so these are stated plainly. They are the part of the picture that silence would otherwise hide.

Oxytocin is an authorised prescription medicine in obstetrics and its adverse effect profile is stated on its regulatory label. The entry above is a methodological critique of the behavioural literature, not a safety summary, and it should not be read as one.
The behavioural literature's central problem is not that effects were disproved but that early effect sizes did not survive better-powered and pre-registered replication. Any confident claim about oxytocin and trust, bonding or social behaviour is running ahead of what the pooled evidence supports.
Cross-reactivity with vasopressin receptors is a known confounder that much of the behavioural work did not control for.
How much of an administered dose reaches the central nervous system is itself contested, which undermines interpretation of studies that assume it does.
Research-grade material is not the authorised obstetric medicine and carries none of its regulatory guarantees.

Common questions

Is oxytocin an approved medicine?: Yes, and has been for decades — a widely used prescription medicine in obstetrics, acting on uterine smooth muscle. That use is well established and not in dispute.
Does oxytocin make people more trusting?: The early studies reported striking effects and the later, better-powered ones did not reproduce them at that size. Pooled analyses across clinical populations report limited and inconsistent effects, so the honest answer is that the literature does not support the claim as confidently as its popular reputation suggests.
Why is oxytocin research considered a replication problem?: Because effect sizes fell substantially as sample sizes grew and pre-registration became standard, and a methodological review identified design and analysis shortcomings in the existing studies. It is now a standard teaching example in the reproducibility literature.
Why does vasopressin matter when reading oxytocin studies?: The two hormones differ by only two amino acids and cross-react at each other's receptors. An effect attributed to oxytocin signalling may not be oxytocin-receptor-specific, and much of the behavioural work did not control for this.
What is oxytocin's place in chemistry history?: It was the first peptide hormone to be sequenced and totally synthesised, by du Vigneaud in 1953, work that won the 1955 Nobel Prize in Chemistry.

Compounds covered

The reference page for each compound this article discusses.

Oxytocin

HCG chorionic gonadotropin: what the research says
A long-established fertility medicine, and a literature that is almost entirely about treating diagnosed endocrine deficiency. Not about weight loss.
Semax: what the research says
An ACTH(4-10) analogue registered as a medicine in Russia and unknown to Western regulators. What the BDNF work reported, and why the English record looks thin.
How to reconstitute lyophilised peptides
How to reconstitute a lyophilised peptide with bacteriostatic water without damaging it: why you run the liquid down the vial wall and never shake it.

About this article

Everything reported here comes from published research, and each finding names the model the study used — cell culture, rat, or human. Findings in one model do not transfer to another, most of the work described is preclinical, and none of it is a claim that a compound is safe or effective for any purpose. Nothing on this page describes doses, routes of administration, or use in a person.

Approval status varies by compound and by country. A few of the substances described are the active ingredient of medicines authorised in the EU; most have no marketing authorisation anywhere and have never been assessed by a regulator. Neither is supplied as a medicine here. All material supplied by ASSAY is sold for in-vitro laboratory research only, and is not a drug, food, cosmetic or medical device, and not for human or veterinary use.

All guides